Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. (17th November 2021)

• Record Type: Journal Article
• Authors: Aimo, Alberto; Vergaro, Giuseppe; Passino, Claudio; Clerico, Aldo
• Is Part Of: Critical reviews in clinical laboratory sciences. Volume 58:Number 8(2021)
• Page Start: 530
• Page End: 545
• Publication Date: 2021-11-17
• Subjects: Renin -- angiotensin -- aldosterone -- cardiac natriuretic peptides -- ACE; Diagnosis, laboratory -- Periodicals; Medicine, Clinical -- Periodicals; 616.07
• DOI: 10.1080/10408363.2021.1942782
• Languages: English
• ISSNs: 1040-8363

Abstract

Abstract: Despite the progressive improvements in diagnosis and therapy during the first 20 years of this century, the morbidity and mortality of patients with heart failure (HF) remain high, resulting in an enormous health and economic burden. Only a further improvement in understanding the pathophysiological mechanisms related to the development of cardiac injury and dysfunction can allow more innovative and personalized approaches to HF management. The renin–angiotensin system (RAS) has a critical role in cardiovascular physiology by regulating blood pressure and electrolyte balance. The RAS is mainly regulated by both angiotensin converting enzyme (ACE) and type 2 angiotensin converting enzyme (ACE2). However, the balance between the various peptides and peptidases constituting the RAS/ACE pathway remains in great part unraveled in patients with HF. This review summarizes the role of the RAS/ACE axis in cardiac physiology and HF pathophysiology as well as some analytical issues relevant to the clinical and laboratory assessment of inter-relationships between these two systems. There is evidence that RAS peptides represent a dynamic network of peptides, which are altered in different HF states and influenced by medical therapy. However, the mechanisms of signal transduction have not been fully elucidated under physiological and pathophysiological conditions. Further investigations are necessary to explore novel molecular mechanisms related to the RAS, which will provide alternative therapeutic agents. Moreover, monitoring the circulating levels of active RAS peptides in HF patients may enable a personalized approach by facilitating assessment of the pathophysiological status of several cardiovascular diseases and thus better selection of therapies for HF patients.